Ieq Capital LLC Makes New Investment in Treace Medical Concepts, Inc. $TMCI

Ieq Capital LLC purchased a new stake in Treace Medical Concepts, Inc. (NASDAQ:TMCI) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 109,762 shares of the company’s stock, valued at approximately $437,000. Ieq Capital LLC owned approximately 0.17% of Treace Medical Concepts as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Renaissance Technologies LLC bought a new stake in Treace Medical Concepts during the first quarter valued at about $701,000. GSA Capital Partners LLP boosted its stake in shares of Treace Medical Concepts by 212.5% in the fourth quarter. GSA Capital Partners LLP now owns 347,755 shares of the company’s stock worth $852,000 after acquiring an additional 236,477 shares during the period. Gagnon Advisors LLC boosted its stake in shares of Treace Medical Concepts by 58.4% in the fourth quarter. Gagnon Advisors LLC now owns 1,534,034 shares of the company’s stock worth $3,758,000 after acquiring an additional 565,570 shares during the period. Gagnon Securities LLC grew its position in shares of Treace Medical Concepts by 37.7% during the fourth quarter. Gagnon Securities LLC now owns 3,110,575 shares of the company’s stock worth $7,621,000 after purchasing an additional 852,337 shares in the last quarter. Finally, First Eagle Investment Management LLC grew its position in shares of Treace Medical Concepts by 18.1% during the fourth quarter. First Eagle Investment Management LLC now owns 1,462,983 shares of the company’s stock worth $3,584,000 after purchasing an additional 224,088 shares in the last quarter. Institutional investors and hedge funds own 84.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on TMCI shares. Weiss Ratings downgraded Treace Medical Concepts from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. Wall Street Zen upgraded shares of Treace Medical Concepts from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Truist Financial raised their target price on shares of Treace Medical Concepts from $4.00 to $5.00 and gave the company a “hold” rating in a research note on Monday, August 10th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Treace Medical Concepts currently has an average rating of “Reduce” and a consensus target price of $5.17.

Insider Transactions at Treace Medical Concepts

In other Treace Medical Concepts news, CEO John T. Treace bought 50,000 shares of Treace Medical Concepts stock in a transaction on Monday, June 1st. The shares were acquired at an average price of $3.56 per share, for a total transaction of $178,000.00. Following the completion of the purchase, the chief executive officer directly owned 7,323,833 shares in the company, valued at approximately $26,072,845.48. This trade represents a 0.69% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders acquired 158,261 shares of company stock worth $635,613. 23.42% of the stock is owned by insiders.

Treace Medical Concepts Stock Up 1.1%

Shares of TMCI opened at $4.65 on Friday. The company has a quick ratio of 1.95, a current ratio of 2.90 and a debt-to-equity ratio of 0.83. The business has a fifty day moving average of $4.41 and a 200 day moving average of $2.98. The company has a market cap of $302.44 million, a PE ratio of -5.00 and a beta of 1.37. Treace Medical Concepts, Inc. has a 52-week low of $1.17 and a 52-week high of $7.63.

Treace Medical Concepts (NASDAQ:TMCI) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06. The business had revenue of $45.38 million for the quarter, compared to analysts’ expectations of $44.02 million. Treace Medical Concepts had a negative net margin of 28.99% and a negative return on equity of 71.37%. On average, sell-side analysts expect that Treace Medical Concepts, Inc. will post -0.83 EPS for the current year.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.